Anna Jenkinson

High level European officials are predicting an important spring for EU public procurement, as Europe tries to catch up on the US

A more flexible grant system will generate more innovation and create more value than the current Framework Programme 7’s €6.1B health research budget

Disagreement on allowing products from the offspring of cloned animals onto the market in Europe has left plans to update all regulations on novel foods in tatters

Therapies based on human embryonic stem cells should not be granted patents, according to the latest opinion from the Court of Justice of the European Union. If confirmed, this will have a major impact on stem cell research in Europe and on the European life sciences industry as a whole

Eurolight, a new venture capital firm set up to specialise in photonics start-ups in Europe, outlined its investment plans as members of the industry gathered to discuss the state of play in this critical technology. Photonics has been singled out by the Commission as one of five fields central to future growth prospects

The European Commission proposes a joined-up approach to research and innovation, in a move that could have profound implications for European research funding

There’s still little progress to report in Europe’s innovation performance, as the gap with Japan and the US widens further, and upcoming competitors China and Brazil are catching up, according to the EU’s latest reckoning in the 2010 Innovation Union Scoreboard.

It’s a year since Maire Geoghegan-Quinn stepped into her post, promising to be a woman of action. This week came the first concrete fruits of that pledge, with a pruning of R&D grant rules. But how much progress is the Commissioner for Research, Innovation and Science judged to have made elsewhere?

The European Commission has opened an official consultation procedure, in preparation of possible changes to public procurement rules.